BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL

[1]  P. Corradini,et al.  TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy , 2016 .

[2]  C. Martínez,et al.  Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO) , 2016 .

[3]  R. Advani,et al.  Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial , 2016 .

[4]  A. Santoro,et al.  Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. García-Sanz.  WM, MYD88, and CXCR4: following the thread. , 2016, Blood.

[6]  L. Larocca,et al.  CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma , 2016, Cancer medicine.

[7]  I. Barista,et al.  Gemcitabine in Combination with Oxaliplatin (GEMOX) As a Salvage Regimen in Patients with Relapsed/Refractory Hodgkin's Lymphoma , 2015 .

[8]  R. Advani,et al.  Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma , 2015 .

[9]  A. Zelenetz,et al.  PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[10]  S. Ponader,et al.  Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma , 2013, American journal of hematology.

[11]  A. Zelenetz,et al.  Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Neuberg,et al.  Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. , 2012, Blood.

[13]  R. Houot,et al.  Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Gandhi,et al.  Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2012, Clinical Cancer Research.

[15]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Pruim,et al.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma , 2012, Haematologica.

[18]  M. Crump,et al.  How I treat relapsed and refractory Hodgkin lymphoma. , 2011, Blood.

[19]  A. Zelenetz,et al.  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Santoro,et al.  Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. , 2007, Haematologica.

[22]  Damon L. Meyer,et al.  Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates* , 2006, Journal of Biological Chemistry.

[23]  K. Ding,et al.  Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  B. Angus,et al.  Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Pizzolo,et al.  Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  G. Salles,et al.  Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. S. San Miguel,et al.  Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's disease , 2001, British journal of haematology.

[28]  A. Zelenetz,et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.

[29]  J. Bosq,et al.  VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease , 1998, Bone Marrow Transplantation.

[30]  M. Chilosi,et al.  Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. , 1998, Blood.

[31]  G. Nadali,et al.  Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Stein,et al.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.

[33]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.